Target Atlas in Oncology Drug Development: Targeted Therapies

Abstract

With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of potential drug targets in the form of altered genes, proteins or corrupted pathways. Drug targets are the critical link between drugs and their role in the treatment of medical disorders.

This report, Target Atlas in Oncology Drug Development: Targeted Therapies, is written for you to identify your competition and understand which targeting strategies are at work within the cancer drug development landscape. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Targeted Therapy Strategies in Cancer

• Apoptosis
• Angiogenesis/VDA/VTA
• Antibodies
• Immunomodulators & Vaccines
• Protein Kinase Inhibitors

Each report subject covers:

• Compound strategies based on sub-cellular localization of cancer drug targets
• The Cancer Genome Project and cancer drug targets
• Expression levels of identified drug targets in selected tumor type
• Pathway analysis of cancer drug targets
• Target-target interactions among identified cancer targets
• Structure-based drug design in 9 s stimulated by available structure data on biological targets
• Unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
• Drug-target interactome
• The progression and maturity of cancer targets: New and unique cancer drug targets
• Targeted therapy specific reports deal with all drug targets by cancer indication.
• Cancer drug target profiles by investigator

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer drugs. It will assist you in lead commercial analysis and product strategy thinking to build and nurture current and future portfolio of drug candidates and R&D alliances. This report will help you to streamline your analysis of new as well as of established drug targets, when looking for clinical proofs, indication selection, competitive environment etc.

Table of Contents

Targeted Therapy Strategies in Cancer

Apoptosis

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Figures
• 4.2 List of Tables

5 Introduction

6 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Apoptopic Drug Targets

• 7.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of Apoptopic Drug Targets in Human

• 8.1 Expression in Normal Tissues and Cancer Tissues
• 8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Drug Targets of Apoptopic Drugs

10 Protein-Protein Interactions Between Identified Apoptopic Drug Targets

11 Available Biological Structure Data on Apoptopic Drug Targets

12 Drug Target Profiles of Apoptopic Drug Targets in Oncology

• 12.1.1 Auxiliary transport protein activity
• 12.1.2 Carboxy-lyase activity
• 12.1.3 Catalytic activity
• 12.1.4 Cell adhesion molecule activity
• 12.1.5 Chaperone activity
• 12.1.6 Complement activity
• 12.1.7 Cysteine-type peptidase activity
• 12.1.8 Cytokine activity
• 12.1.9 DNA topoisomerase activity
• 12.1.10 Glutathione transferase activity
• 12.1.11 Hormone activity
• 12.1.12 Hydrolase activity
• 12.1.13 Intracellular ligand-gated ion channel activity
• 12.1.14 Kinase activity
• 12.1.15 Kinase regulator activity
• 12.1.16 Ligase activity
• 12.1.17 Lipid kinase activity
• 12.1.18 Metallopeptidase activity
• 12.1.19 Molecular function unknown
• 12.1.20 Motor activity
• 12.1.21 Oxidoreductase activity
• 12.1.22 Peptide hormone
• 12.1.23 Peroxidase activity
• 12.1.24 Protein binding
• 12.1.25 Protein serine/threonine kinase activity
• 12.1.26 Protein threonine/tyrosine kinase activity
• 12.1.27 Protein-tyrosine kinase activity
• 12.1.28 Receptor activity
• 12.1.29 Receptor binding
• 12.1.30 Receptor signaling complex scaffold activity
• 12.1.31 Receptor signaling protein serine/threonine kinase activity
• 12.1.32 RNA binding
• 12.1.33 Structural constituent of cytoskeleton
• 12.1.34 Superoxide dismutase activity
• 12.1.35 T cell receptor activity
• 12.1.36 Transcription factor activity
• 12.1.37 Transcription regulator activity
• 12.1.38 Transferase activity
• 12.1.39 Translation regulator activity
• 12.1.40 Transmembrane receptor activity
• 12.1.41 Transmembrane receptor protein tyrosine kinase activity
• 12.1.42 Transporter activity

13 Apoptopic Drug Target Mix by Development Stage

14 Apoptopic Drug Target Mix by Cancer Indication

• 14.1 Basal Cell Cancer
• 14.2 Biliary Cancer
• 14.3 Bladder Cancer
• 14.4 Bone Cancer
• 14.5 Brain Cancer
• 14.6 Breast Cancer
• 14.7 Carcinoid Tumor
• 14.8 Cervical Cancer
• 14.9 Chemotherapy-induced Neutropenia
• 14.10 Colorectal Cancer
• 14.11 Endometrial Cancer
• 14.12 Fallopian Tube Cancer
• 14.13 Gastrointestinal Cancer
  • 14.13.1 Gastrointestinal Stomach Cancer
  • 14.13.2 Gastrointestinal Stromal Cancer
• 14.14 Head and Neck Cancer
• 14.15 Leukemia
  • 14.15.1 Acute Lymphocytic Leukemia
  • 14.15.2 Acute Myelogenous Leukemia
  • 14.15.3 Chronic Lymphocytic Leukemia
  • 14.15.4 Chronic Myelogenous Leukemia
• 14.16 Liver Cancer
• 14.17 Lung Cancer
  • 14.17.1 Non-Small Cell Lung Cancer
  • 14.17.2 Small Cell Lung Cancer
• 14.18 Lymphoma
  • 14.18.1 B-cell Lymphoma
  • 14.18.2 Hodgkin' s Lymphoma
  • 14.18.3 non-Hodgkin' s Lymphoma
  • 14.18.4 T-cell Lymphoma
• 14.19 Melanoma
• 14.20 Mesothelioma
• 14.21 Myelodysplastic Syndrome
• 14.22 Myeloma
• 14.23 Nasopharyngeal Cancer
• 14.24 Oesophageal Cancer
• 14.25 Oral Cancer
• 14.26 Ovarian Cancer
• 14.27 Pancreatic Cancer
• 14.28 Peritoneal Cancer
• 14.29 Prostate Cancer
• 14.30 Renal Cancer
• 14.31 Sarcoma
  • 14.31.1 Leiomyo Sarcoma
• 14.32 Squamous Cell Cancer
• 14.33 Testicular Cancer
• 14.34 Thymoma Cancer
• 14.35 Thyroid Cancer

15 Apoptopic Drugs and their Targets by Companies

• 15.1 Australia
• 15.2 Canada
• 15.3 China
• 15.4 Denmark
• 15.5 Germany
• 15.6 Israel
• 15.7 Japan
• 15.8 South Korea
• 15.9 Spain
• 15.10 Switzerland
• 15.11 Taiwan
• 15.12 United Kingdom
• 15.13 USA

16 Disclaimer

17 Drug Index

18 Company Index

List of Figures

• Figure 1: Distribution of Compound Types Among Apoptopic Drugs
• Figure 2: Primary Sub-cellular Localization of Drug Targets

List of Tables

• Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
• Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
• Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets
• Table 4: Pathway Summary
• Table 5: Drug Targets Without any Identified Assigned Pathways
• Table 6: Pathway Profile According to BioCarta of the Drug Targets Belonging to Apoptopic Drugs
• Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta
• Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging to Apoptopic Drugs
• Table 9: Drug Targets within the Apoptosis Pathway According to KEGG
• Table 10: Apoptopic Drugs Targeting Major Singaling Pathways
• Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug Targets
• Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction with other Drug Targets
• Table 13: Number of Available Biological Structures on Apoptopic Drug Targets
• Table 14: Overview of Drug Target Profile Themes
• Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and Developmental Projects by Developmental Stage
• Table 16: Apoptopic Drug Target Mixes by Development
• Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer Indication
• Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Drug
• Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
• Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
• Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
• Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
• Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
• Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
• Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug
• Table 26: Apoptopic Drug Target Mix for the Treatment of Chemotherapy-induced Neutropenia According to Compound Type and Developmental Stage of Drug
• Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
• Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
• Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
• Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
• Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia (general) According to the Compound Type and Developmental Stage of Drug
• Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
• Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer (general) According to the Compound Type and Developmental Stage of Drug
• Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma (general) According to the Compound Type and Developmental Stage of Drug
• Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug 216
• Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
• Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
• Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
• Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
• Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer According to the Compound Type and Developmental Stage of Drug
• Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
• Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
• Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
• Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general) According to the Compound Type and Developmental Stage of Drug
• Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
• Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
• Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer According to the Compound Type and Developmental Stage of Drug
• Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer According to the Compound Type and Developmental Stage of Drug
• Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
• Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Australia
• Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Canada
• Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in China
• Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Denmark
• Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Germany
• Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Israel
• Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Japan
• Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in South Korea
• Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Spain
• Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Switzerland
• Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Taiwan
• Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in United Kingdom
• Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by Company in USA

Angiogenesis/VDA/VTA

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Figures
• 4.2 List of Tables

5 How to Use this Report

6 Anti-Angiogenic Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Angiogenesis Drug Targets

• 7.1 Anti-Angiogenic Drug Targets Present in the Cancer Gene Census and in the Catalogue Somatic Mutations in Cancer

8 Protein Expression Profiles of Anti-Angiogenic Drug Targets in Human

• 8.1 Expression in Normal Tissues and Cancer Tissues
• 8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Anti-Angiogenic Drugs

10 Protein-Protein Interactions Among Identified Anti-Angiogenic Drug Targets

11 Available Biological Structure Data on Anti-Angiogenic Drug Targets

12 Drug Target Profiles of Anti-angiogenesis Drug Targets in Oncology

• 12.1.1 Carboxy-Lyase Activity
• 12.1.2 Catalytic Activity
• 12.1.3 Cell Adhesion Molecule Activity
• 12.1.4 Chaperone Activity
• 12.1.5 Cofactor Binding
• 12.1.6 Cysteine-Type Peptidase Activity
• 12.1.7 Cytokine Activity
• 12.1.8 DNA Topoisomerase Activity
• 12.1.9 DNA-Directed DNA Polymerase Activity
• 12.1.10 Extracellular Matrix Structural Constituent
• 12.1.11 G-Protein Coupled Receptor Activity
• 12.1.12 Growth Factor Activity
• 12.1.13 GTPase Activity
• 12.1.14 Hydrolase Activity
• 12.1.15 Kinase Activity
• 12.1.16 Lipid Kinase Activity
• 12.1.17 Metallopeptidase Activity
• 12.1.18 Molecular Function Unknown
• 12.1.19 Motor Activity
• 12.1.20 Peptidase Activity
• 12.1.21 Protease Inhibitor Activity
• 12.1.22 Protein Serine/Threonine Kinase Activity
• 12.1.23 Protein-Tyrosine Kinase Activity
• 12.1.24 Receptor Activity
• 12.1.25 Receptor Binding
• 12.1.26 Serine-Type Peptidase Activity
• 12.1.27 Structural Constituent of Cytoskeleton
• 12.1.28 Superoxide Dismutase Activity
• 12.1.29 Transcription Factor Activity
• 12.1.30 Transcription Regulator Activity
• 12.1.31 Translation Regulator Activity
• 12.1.32 Transmembrane Receptor Activity
• 12.1.33 Transmembrane Receptor Protein Tyrosine Kinase Activity
• 12.1.34 Transporter Activity

13 The Drug-Protein Interactome of Anti-Angiogenic Drugs

14 The Progression and Maturity of Anti-Angiogenic Drug Target Combinations

• 14.1 Target Profiles of Anti-Angiogenic Drugs on the Market
• 14.2 New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
• 14.3 New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
• 14.4 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
• 14.5 New Anti-Angiogenic Drug Target Combinations in Preclinical Development
• 14.6 Development Profiles of All Identified Anti-Angiogenic Drug Target Combinations

15 Anti-Angiogenic Drug Target Mix by Cancer Indication

• 15.1 Adrenal Cancer
• 15.2 Biliary Cancer
• 15.3 Bladder Cancer
• 15.4 Bone Cancer
• 15.5 Brain Cancer
• 15.6 Breast Cancer
• 15.7 Carcinoid Tumor
• 15.8 Cervical Cancer
• 15.9 Chemotherapy-Induced Infection
• 15.10 Colorectal Cancer
• 15.11 Endometrial Cancer
• 15.12 Fallopian Tube Cancer
• 15.13 Gastrointestinal Cancer
  • 15.13.1 Gastrointestinal Stomach Cancer
  • 15.13.2 Gastrointestinal Stromal Cancer
• 15.14 Head and Neck Cancer
• 15.15 Leukemia
  • 15.15.1 Acute Lymphocytic Leukemia
  • 15.15.2 Acute Myelogenous Leukemia
  • 15.15.3 Chronic Lymphocytic Leukemia
  • 15.15.4 Chronic Myelogenous Leukemia
• 15.16 Liver Cancer
• 15.17 Lung Cancer
  • 15.17.1 Non-Small Cell Lung Cancer
  • 15.17.2 Small Cell Lung Cancer
• 15.18 Lymphoma
  • 15.18.1 B-Cell Lymphoma
  • 15.18.2 Hodgkin' s Lymphoma
  • 15.18.3 Non-Hodgkin' s Lymphoma
• 15.19 Melanoma
• 15.20 Mesothelioma
• 15.21 Myelodysplastic Syndrome
• 15.22 Myeloma
• 15.23 Nasopharyngeal Cancer
• 15.24 Oesophageal Cancer
• 15.25 Ovarian Cancer
• 15.26 Pancreatic Cancer
• 15.27 Peritoneal Cancer
• 15.28 Prostate Cancer
• 15.29 Renal Cancer
• 15.30 Sarcoma
  • 15.30.1 Leiomyo Sarcoma
• 15.31 Squamous Cell Cancer
• 15.32 Thyroid Cancer

16 Anti-Angiogenic Drugs and Their Targets by Companies

• 16.1 Australia
• 16.2 Austria
• 16.3 Belgium
• 16.4 Canada
• 16.5 China
• 16.6 Denmark
• 16.7 France
• 16.8 Germany
• 16.9 Israel
• 16.10 Japan
• 16.11 Netherlands
• 16.12 South Korea
• 16.13 Spain
• 16.14 Sweden
• 16.15 Switzerland
• 16.16 United Kingdom
• 16.17 USA

17 Disclaimer

18 Drug Index

19 Company Index

List of Figures

• Figure 1: Distribution of Compound Types Among Anti-Angiogenic Drugs
• Figure 2: Primary Sub-cellular Localization of Drug Targets
• Figure 3: Visualization of Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
• Figure 4: The Drug-Protein Interactome of Anti-Angiogenic Drugs
• Figure 5: Direct Head-to-Head Targeting Interactome of Anti-Angiogenic Drugs

List of Tables

• Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
• Table 2: Drug Targets of Anti-Angiogenic Drugs Present in the Catalogue of Somatic Mutations in Cancer and the Cancer Gene Census
• Table 3: Available Protein Expression Profiles of Anti-Angiogenic Drug Targets
• Table 4: Pathway Summary
• Table 5: Drug Targets Without any Identified Assigned Pathways
• Table 6: Pathway Profile According to BioCarta of the Anti-Angiogenic Drug Targets
• Table 7: Pathway Profile According to KEGG of the Anti-Angiogenic Drug Targets
• Table 8: Anti-Angiogenic Drugs Targeting Major Singaling Pathways
• Table 9: Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
• Table 10: Number of Available Biological Structures on Anti-Angiogenic Drug Targets
• Table 11: Overview of Drug Target Profile Themes
• Table 12: Drug-Protein Clusters in the Anti-Angiogenic Interactome
• Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage
• Table 14: Target Profiles of Anti-Angiogenic Drugs on the Market
• Table 15: New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
• Table 16: New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
• Table 17 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
• Table 18: New Anti-Angiogenic Drug Target Combinations in Preclinical Development
• Table 19: The Progression, Maturity and Comptitive Comparison of Anti-Angiogenic Drug Target Mixes in Development
• Table 20: Number of Unique Anti-angiogenic Drug Target Mixes Reported by Cancer Indication
• Table 21: The Competitive Situation on Bevacizumab (Avastin)
• Table 22: Anti-angiogenic Drug Target Mix for the Treatment of Adrenal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 23: Anti-angiogenic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
• Table 24: Anti-angiogenic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
• Table 25: Anti-angiogenic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
• Table 26: Anti-angiogenic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
• Table 27: Anti-angiogenic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
• Table 28: Anti-angiogenic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
• Table 29: Anti-angiogenic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug
• Table 30: Anti-angiogenic Drug Target Mix for the Treatment of Chemotherapy-induced Infection According to the Compound Type and Developmental Stage of Drug
• Table 31: Anti-angiogenic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 32: Anti-angiogenic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
• Table 33: Anti-angiogenic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
• Table 34: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Cancer (General) According the Compound Type and Developmental Stage of Drug
• Table 35: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According the Compound Type and Developmental Stage of Drug
• Table 36: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 37: Anti-angiogenic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
• Table 38: Anti-angiogenic Drug Target Mix for the Treatment of Leukemia (General) According to the Compound Type and Developmental Stage of Drug
• Table 39: Anti-angiogenic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
• Table 40: Anti-angiogenic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to Compound Type and Developmental Stage of Drug
• Table 41: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
• Table 42: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
• Table 43: Anti-angiogenic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
• Table 44: Anti-angiogenic Drug Target Mix for the Treatment of Lung Cancer (General) According to the Compound Type and Developmental Stage of Drug
• Table 45: Anti-angiogenic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 46: Anti-angiogenic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
• Table 47: Anti-angiogenic Drug Target Mix for the Treatment of Lymphoma (General) According to the Compound Type and Developmental Stage of Drug
• Table 48: Anti-angiogenic Drug Target Mix for the Treatment of B-Cell Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 49: Anti-angiogenic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 50: Anti-angiogenic Drug Target Mix for the Treatment of Non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
• Table 51: Anti-angiogenic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
• Table 52: Anti-angiogenic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
• Table 53: Anti-angiogenic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
• Table 54: Anti-angiogenic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
• Table 55: Anti-angiogenic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 56: Anti-angiogenic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 57: Anti-angiogenic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
• Table 58: Anti-angiogenic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
• Table 59: Anti-angiogenic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 60: Anti-angiogenic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
• Table 61: Anti-angiogenic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
• Table 62: Anti-angiogenic Drug Target Mix for the Treatment of Sarcoma (General) According to the Compound Type and Developmental Stage of Drug
• Table 63: Anti-angiogenic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
• Table 64: Anti-angiogenic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
• Table 65: Anti-angiogenic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
• Table 66: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Australia
• Table 67: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Austria
• Table 68: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Belgium
• Table 69: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Canada
• Table 70: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in China
• Table 71: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Denmark
• Table 72: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in France
• Table 73; Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Germany
• Table 74: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Israel
• Table 75: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Japan
• Table 76: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in the Netherlands
• Table 77: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
• Table 78: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
• Table 79: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Sweden
• Table 80: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Switzerland
• Table 81: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in United Kingdom
• Table 82: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in USA

Antibodies

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Figures
• 4.2 List of Tables

5 How to Use this Report

6 Antibody Target Localization

7 The Cancer Genome Project and Antibody Targets

• 7.1 Antibody Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of Antibody Drug Targets in Human

• 8.1 Expression in Normal Tissues and Cancer Tissues
• 8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Antibody Drugs

10 Protein-Protein Interactions Among Identified Antibody Targets

11 Available Biological Structure Data on Antibody Targets

12 Drug Target Profiles of Antibody Targets in Oncology

• 12.1.1 Auxiliary Transport Protein Activity
• 12.1.2 Carboxypeptidase Activity
• 12.1.3 Catalytic Activity
• 12.1.4 Cell Adhesion Molecule Activity
• 12.1.5 Chemokine Activity
• 12.1.6 Cofactor Binding
• 12.1.7 Complement Activity
• 12.1.8 Cytokine Activity
• 12.1.9 DNA Topoisomerase Activity
• 12.1.10 Extracellular Matrix Structural Constituent
• 12.1.11 G-Protein Coupled Receptor Activity
• 12.1.12 Growth Factor Activity
• 12.1.13 Hormone Activity
• 12.1.14 Hydrolase Activity
• 12.1.15 Intracellular Ligand-Gated Ion Channel Activity
• 12.1.16 Metallopeptidase Activity
• 12.1.17 MHC Class I Receptor Activity
• 12.1.18 Molecular Function Unknown
• 12.1.19 Oxidoreductase Activity
• 12.1.20 Peptidase Activity
• 12.1.21 Protease Inhibitor Activity
• 12.1.22 Protein Binding
• 12.1.23 Receptor Activity
• 12.1.24 Receptor Binding
• 12.1.25 Receptor Signaling Complex Scaffold Activity
• 12.1.26 RNA-Directed DNA Polymerase Activity
• 12.1.27 Serine-Type Peptidase Activity
• 12.1.28 T Cell Receptor Activity
• 12.1.29 Translation Regulator Activity
• 12.1.30 Transmembrane Receptor Activity
• 12.1.31 Transmembrane Receptor Protein Tyrosine Kinase Activity
• 12.1.32 Unclassified

13 The Antibody-Target Interactome

14 The Progression and Maturity of Antibody Targets in Oncology: The Preclinical Explosion

• 14.1 Target Profiles of Cancer Antibodies in Pre-Registration or on the Market
• 14.2 New Cancer Antibody Targets in Phase III Clinical Development
• 14.3 New Cancer Antibody Targets in Phase II Clinical Development
• 14.4 New Cancer Antibody Targets in Phase I Clinical Development
• 14.5 New Cancer Antibody Targets in Preclinical Development
• 14.6 Development Profiles of All Identified Cancer Antibody Targets

15 Competitive Peer Group Profiling of Antibody Drugs by Cancer Indication

• 15.1 Biliary Cancer
• 15.2 Bladder Cancer
• 15.3 Bone Cancer
• 15.4 Brain Cancer
• 15.5 Breast Cancer
• 15.6 Cervical Cancer
• 15.7 Colorectal Cancer
• 15.8 Endometrial Cancer
• 15.9 Fallopian Tube Cancer
• 15.10 Gastrointestinal Cancer
• 15.10.1 Gastrointestinal Stomach Cancer
• 15.11 Head and Neck Cancer
• 15.12 Leukemia
  • 15.12.1 Acute Lymphocytic Leukemia
  • 15.12.2 Acute Myelogenous Leukemia
  • 15.12.3 Chronic Lymphocytic Leukemia
  • 15.12.4 Chronic Myelogenous Leukemia
• 15.13 Liver Cancer
• 15.14 Lung Cancer
  • 15.14.1 Non-Small Cell Lung Cancer
  • 15.14.2 Small Cell Lung Cancer
• 15.15 Lymphoma
  • 15.15.1 B-Cell Lymphoma
  • 15.15.2 Hodgkin' s Lymphoma
  • 15.15.3 Non-Hodgkin' s Lymphoma
  • 15.15.4 T-Cell Lymphoma
• 15.16 Melanoma
• 15.17 Mesothelioma
• 15.18 Myelodysplastic Syndrome
• 15.19 Myeloma
• 15.20 Nasopharyngeal Cancer
• 15.21 Neuroblastoma Cancer
• 15.22 Oesophageal Cancer
• 15.23 Ovarian Cancer
• 15.24 Pancreatic Cancer
• 15.25 Peritoneal Cancer
• 15.26 Prostate Cancer
• 15.27 Renal Cancer
• 15.28 Sarcoma
• 15.29 Supportive Care Indications
  • 15.29.1 Chemotherapy-Induced Bone Marrow Injury
  • 15.29.2 Chemotherapy-Induced Anemia
• 15.30 Thyroid Cancer

16 Cancer Antibodies and Their Targets by Companies

• 16.1 Australia
• 16.2 Belgium
• 16.3 Brazil
• 16.4 Canada
• 16.5 China
• 16.6 Cuba
• 16.7 Denmark
• 16.8 France
• 16.9 Germany
• 16.10 Israel
• 16.11 Italy
• 16.12 Japan
• 16.13 Netherlands
• 16.14 New Zealand
• 16.15 Norway
• 16.16 South Korea
• 16.17 Sweden
• 16.18 Switzerland
• 16.19 United Kingdom
• 16.20 USA
• 16.21 Non Industrial Bodies

17 Disclaimer

18 Drug Index

19 Company Index

List of Figures

• Figure 1: Primary Sub-cellular Localization of Drug Targets
• Figure 2: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
• Figure 3: The Drug-Protein Interactome of Antibody Drugs in Oncology
• Figure 4: Direct Head-to-Head Targeting Interactome of Cancer Antibody Drugs
• Figure 5: Competitive Peer Group Profiling Example

List of Tables

• Table 1: Primary and Alternate Localization of Antibody Drug Targets
• Table 2: Drug Targets of Cancer Antibodies Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
• Table 3: Available Protein Expression Profiles of Antibody Drug Targets
• Table 4: Pathway Summary
• Table 5: Drug Targets Without any Identified Assigned Pathways
• Table 6: Pathway Profile According to BioCarta of Cancer Antibody Drug Targets
• Table 7: Pathway Profile According to KEGG of Cancer Antibody Drug Targets
• Table 8: Cancer Antibodies Targeting Major Singaling Pathways
• Table 9: Protein-Protein Interactions Among Antibody Drug Targets
• Table 10: Number of Available Biological Structures of Cancer Antibody Targets
• Table 11: Overview of Drug Target Profile Themes
• Table 12: Antibody-Protein Interactome Clusters
• Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage
• Table 14: Top 5 Pursued Cancer Antibody Targets
• Table 15: Target Profiles of Cancer Antibodies in Pre-Registration or on the Market
• Table 16: New Cancer Antibody Targets in Phase III Clinical Development
• Table 17: New Cancer Antibody Targets in Phase II Clinical Development
• Table 18 New Cancer Antibody Targets in Phase I Clinical Development
• Table 19: New Cancer Antibody Targets in Preclinical Development
• Table 20: The Progression, Maturity and Competitive Comparison of Antibody Drug Targets in Development
• Table 21: Number of Cancer Antibody Drug Target Mixes Reported by Cancer Indication
• Table 22: Step 1 - Indication Profile of Peer Drugs
• Table 23: Step 2 - All Peer Drugs with Known Cancer Indications
• Table 24: Step 3 - Submarine Peer Drugs
• Table 25: Step 4 -Target Overlap Drugs to Peer Drugs.
• Table 26: Drug Targets of Antibodies for the Treatment of Biliary Cancer According to Developmental Stage of Antibody
• Table 27: Drug Targets of Antibodies for the Treatment of Bladder Cancer According to Developmental Stage of Antibody
• Table 28: Drug Targets of Antibodies for the Treatment of Bone Cancer According to Developmental Stage of Antibody
• Table 29: Drug Targets of Antibodies for the Treatment of Brain Cancer According to Developmental Stage of Antibody
• Table 30: Drug Targets of Antibodies for the Treatment of Breast Cancer According to Developmental Stage of Antibody
• Table 31: Drug Targets of Antibodies for the Treatment of Cervical Cancer According to Developmental Stage of Antibody
• Table 32: Drug Targets of Antibodies for the Treatment of Colorectal Cancer According to Developmental Stage of Antibody
• Table 33: Drug Targets of Antibodies for the Treatment of Endometrial Cancer According to Developmental Stage of Antibody
• Table 34: Drug Targets of Antibodies for the Treatment of Fallopian Tube Cancer According to Developmental Stage of Antibody
• Table 35: Drug Targets of Antibodies for the Treatment of Gastrointestinal Cancer (general) According to Developmental Stage of Antibody
• Table 36: Drug Targets of Antibodies for the Treatment of Gastrointestinal Stomach Cancer According to Developmental Stage of Antibody
• Table 37: Drug Targets of Antibodies for the Treatment of Head and Neck Cancer According to Developmental Stage of Antibody
• Table 38: Drug Targets of Antibodies for the Treatment Leukemia (general) According to Developmental Stage of Antibody
• Table 39: Drug Targets of Antibodies for the Treatment of Acute Lymphocytic Leukemia According to Developmental Stage of Antibody
• Table 40: Drug Targets of Antibodies for the Treatment of Acute Myelogenous Leukemia According to Developmental Stage of Antibody
• Table 41: Drug Targets of Antibodies for the Treatment of Chronic Lymphocytic Leukemia According to Developmental Stage of Antibody
• Table 42: Drug Targets of Antibodies for the Treatment of Chronic Myelogenous Leukemia According to Developmental Stage of Antibody
• Table 43: Drug Targets of Antibodies for the Treatment of Liver Cancer According to Developmental Stage of Antibody
• Table 44: Drug Targets of Antibodies for the Treatment of Lung Cancer (general) According to Developmental Stage of Antibody
• Table 45: Drug Targets of Antibodies for the Treatment of Non Small Cell Lung Cancer According to Developmental Stage of Antibody
• Table 46: Drug Targets of Antibodies for the Treatment of Small Cell Lung Cancer According to Developmental Stage of Antibody
• Table 47: Drug Targets of Antibodies for the Treatment of lymphoma (general) According to Developmental Stage of Antibody
• Table 48: Drug Targets of Antibodies for the Treatment of B cell Lymphoma According to Developmental Stage of Antibody
• Table 49: Drug Targets of Antibodies for the Treatment of Hodgkin' s Lymphoma According to Developmental Stage of Antibody
• Table 50: Drug Targets of Antibodies for the Treatment of Non Hodgkin' s Lymphoma According to Developmental Stage of Antibody
• Table 51: Drug Targets of Antibodies for the Treatment of T cell Lymphoma According to Developmental Stage of Antibody
• Table 52: Drug Targets of Antibodies for the Treatment of Melanoma According to Developmental Stage of Antibody
• Table 53: Drug Targets of Antibodies for the Treatment of Mesothelioma According to Developmental Stage of Antibody
• Table 54: Drug Targets of Antibodies for the Treatment of Myelodysplastic Syndrome According to Developmental Stage of Antibody
• Table 55: Drug Targets of Antibodies for the Treatment of Myeloma According to Developmental Stage of Antibody
• Table 56: Drug Targets of Antibodies for the Treatment of Nasopharyngeal Cancer According to Developmental Stage of Antibody
• Table 57: Drug Targets of Antibodies for the Treatment of Neuroblastoma Cancer According to Developmental Stage of Antibody
• Table 58: Drug Targets of Antibodies for the Treatment of Oesophageal Cancer According to Developmental Stage of Antibody
• Table 59: Drug Targets of Antibodies for the Treatment of Ovarian Cancer According to Developmental Stage of Antibody
• Table 60: Drug Targets of Antibodies for the Treatment of Pancreatic Cancer According to Developmental Stage of Antibody
• Table 61: Drug Targets of Antibodies for the Treatment of Peritoneal Cancer According to Developmental Stage of Antibody
• Table 62: Drug Targets of Antibodies for the Treatment of Prostate Cancer According to Developmental Stage of Antibody
• Table 63: Drug Targets of Antibodies for the Treatment of Renal Cancer According to Developmental Stage of Antibody
• Table 64: Drug Targets of Antibodies for the Treatment of Sarcoma According to Developmental Stage of Antibody
• Table 65: Drug Targets of Antibodies for the Treatment of Chemotherapy-Induced Bone Marrow Injury According to Developmental Stage of Antibody
• Table 66: Drug Targets of Antibodies for the Treatment of Chemotherapy-Induced Anemia According to Developmental Stage of Antibody
• Table 67: Drug Targets of Antibodies for the Treatment of Thyroid Cancer According to Developmental Stage of Antibody
• Table 68: Antibodies with Drug Target Mix and Developmental Projects by Companies in Australia
• Table 69: Antibodies with Drug Target Mix and Developmental Projects by Companies in Belgium
• Table 70: Antibodies with Drug Target Mix and Developmental Projects by Companies in Brazil
• Table 71: Antibodies with Drug Target Mix and Developmental Projects by Companies in Canada
• Table 72: Antibodies with Drug Target Mix and Developmental Projects by Companies in China
• Table 73: Antibodies with Drug Target Mix and Developmental Projects by Companies in Cuba
• Table 74: Antibodies with Drug Target Mix and Developmental Projects by Companies in Denmark
• Table 75: Antibodies with Drug Target Mix and Developmental Projects by Companies in France
• Table 76: Antibodies with Drug Target Mix and Developmental Projects by Companies in Germany
• Table 77: Antibodies with Drug Target Mix and Developmental Projects by Companies in Israel
• Table 78: Antibodies with Drug Target Mix and Developmental Projects by Companies in Italy
• Table 79: Antibodies with Drug Target Mix and Developmental Projects by Companies in Japan
• Table 80: Antibodies with Drug Target Mix and Developmental Projects by Companies in the Netherlands
• Table 81: Antibodies with Drug Target Mix and Developmental Projects by Companies in New Zealand
• Table 82: Antibodies with Drug Target Mix and Developmental Projects by Companies in Norway
• Table 83: Antibodies with Drug Target Mix and Developmental Projects by Companies in South Korea
• Table 84: Antibodies with Drug Target Mix and Developmental Projects by Companies in Sweden
• Table 85: Antibodies with Drug Target Mix and Developmental Projects by Companies in Switzerland
• Table 86: Antibodies with Drug Target Mix and Developmental Projects by Companies in United Kingdom
• Table 87: Antibodies with Drug Target Mix and Developmental Projects by Companies in the USA
• Table 88: Antibodies with Drug Target Mix and Developmental Projects by Non-Industrial Bodies

Immunomodulators & Vaccines

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Figures
• 4.2 List of Tables

5 How to Use this Report

6 Cancer Vaccines Types

7 The Cancer Genome Project and Cancer Vaccine Drug Targets

• 7.1 Cancer Vaccine Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of Cancer Vaccine Drug Targets in Human

• 8.1 Expression in Normal Tissues and Cancer Tissues
• 8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Cancer Vaccine Drugs

10 Protein-Protein Interactions Among Identified Cancer Vaccine Drug Targets

11 Available Biological Structure Data on Cancer Vaccine Drug Targets

12 Drug Target Profiles of Cancer Vaccine Drug Targets in Oncology

• 12.1.1 Acid phosphatase activity
• 12.1.2 Carboxypeptidase activity
• 12.1.3 Catalytic activity
• 12.1.4 Cell adhesion molecule activity
• 12.1.5 Chaperone activity
• 12.1.6 Cofactor binding
• 12.1.7 Complement activity
• 12.1.8 Cytokine activity
• 12.1.9 DNA binding
• 12.1.10 DNA topoisomerase activity
• 12.1.11 DNA-directed DNA polymerase activity
• 12.1.12 Growth factor activity
• 12.1.13 Hormone activity
• 12.1.14 Hydrolase activity
• 12.1.15 Intracellular ligand-gated ion channel activity
• 12.1.16 Kinase binding
• 12.1.17 Kinase regulator activity
• 12.1.18 Metallopeptidase activity
• 12.1.19 MHC class I receptor activity
• 12.1.20 Molecular function unknown
• 12.1.21 Oxidoreductase activity
• 12.1.22 Peptidase activity
• 12.1.23 Peptide hormone
• 12.1.24 Protein binding
• 12.1.25 Protein serine/threonine kinase activity
• 12.1.26 Protein-tyrosine kinase activity
• 12.1.27 Receptor activity
• 12.1.28 Receptor binding
• 12.1.29 Receptor signaling complex scaffold activity
• 12.1.30 RNA-directed DNA polymerase activity
• 12.1.31 Serine-type peptidase activity
• 12.1.32 T cell receptor activity
• 12.1.33 Transcription factor activity
• 12.1.34 Transmembrane receptor activity
• 12.1.35 Transmembrane receptor protein tyrosine kinase activity
• 12.1.36 Transporter activity
• 12.1.37 Viral Protein

13 The Drug-Protein Interactome of Cancer Vaccines

14 The Progression and Maturity of Cancer Vaccine Drug Target Combinations

• 14.1 Target Profiles of Cancer Vaccines in Pre-Registration or on the Market
• 14.2 New Cancer Vaccine Target Combinations in Phase III Clinical Development
• 14.3 New Cancer Vaccine Target Combinations in Phase II Clinical Development
• 14.4 New Cancer Vaccine Target Combinations Phase I Clinical Development
• 14.5 New Cancer Vaccine Target Combinations in Preclinical Development
• 14.6 Development Profiles of All Identified Cancer VaccineTarget Combinations

15 Cancer Vaccine Drug Target Mix by Cancer Indication

• 15.1 Anal Dysplasia
• 15.2 Basal Cell Cancer
• 15.3 Bladder Cancer
• 15.4 Bone Cancer
• 15.5 Brain Cancer
• 15.6 Breast Cancer
• 15.7 Cervical Cancer
• 15.8 Cervical Dysplasia
• 15.9 Chemotherapy-Induced Bone Marrow Injury
  • 15.9.1 Chemotherapy-Induced Neutropenia
• 15.10 Colorectal Cancer
• 15.11 Gastrointestinal Cancer
• 15.12 Head and Neck Cancer
• 15.13 Leukemia
  • 15.13.1 Acute Myelogenous Leukemia
  • 15.13.2 Chronic Lymphocytic Leukemia
  • 15.13.3 Chronic Myelogenous Leukemia
• 15.14 Liver Cancer
• 15.15 Lung Cancer
  • 15.15.1 Non-Small Cell Lung Cancer
  • 15.15.2 Small Cell Lung Cancer
• 15.16 Lymphoma
  • 15.16.1 B-Cell Lymphoma
  • 15.16.2 Non-Hodgkin' s Lymphoma
  • 15.16.3 T-Cell Lymphoma
• 15.17 Myelodysplastic Syndrome
• 15.18 Myeloma
• 15.19 Nasopharyngeal Cancer
• 15.20 Oesophageal Cancer
• 15.21 Ovarian Cancer
• 15.22 Pancreatic Cancer
• 15.23 Prostate Cancer
• 15.24 Renal Cancer
• 15.25 Sarcoma
• 15.26 Skin Cancer
  • 15.26.1 Melanoma
• 15.27 Thyroid Cancer

16 Cancer Vaccine Drugs and Their Targets by Companies

• 16.1 Australia
• 16.2 Canada
• 16.3 China
• 16.4 Denmark
• 16.5 France
• 16.6 Germany
• 16.7 India
• 16.8 Israel
• 16.9 Italy
• 16.10 Japan
• 16.11 Netherlands
• 16.12 Norway
• 16.13 South Korea
• 16.14 Switzerland
• 16.15 United Kingdom
• 16.16 USA
• 16.17 Non-Industrial Bodies

17 Disclaimer

18 Drug Index

19 Company Index

List of Figures

• Figure 1: Distribution of Compound Types Among Cancer Vaccines
• Figure 2: Primary Sub-cellular Localization of Drug Targets
• Figure 3: Visualization of Protein-Protein Interactions Among Cancer Vaccine Drug Targets
• Figure 4: The Vaccine-Protein Interactome of Cancer Vaccines
• Figure 5: Direct Head-to-Head Targeting Interactome of Cancer Vaccines

List of Tables

• Table 2: Drug Targets of Cancer Vaccines Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
• Table 3: Available Protein Expression Profiles of Cancer Vaccine Drug Targets
• Table 4: Pathway Summary
• Table 5: Drug Targets Without any Identified Assigned Pathways
• Table 6: Pathway Profile According to BioCarta of Cancer Vaccine Targets
• Table 7: Pathway Profile According to KEGG of Cancer Vaccine Targets
• Table 8: Cancer Vaccines Targeting Major Singaling Pathways
• Table 9: Protein-Protein Interactions Among Cancer Vaccine Drug Targets
• Table 10: Number of Available Biological Structures on Cancer Vaccine Targets
• Table 11: Overview of Drug Target Profile Themes
• Table 12: Vaccine-Protein Target Clusters in the Cancer Vaccine Drug Target Interactome
• Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and Presence of New Drug Target Mixes by Developmental Stage
• Table 14: Target Profiles of Cancer Vaccines in Pre-Registration or on the Market
• Table 15: New Cancer Vaccine Drug Target Combinations in Phase III Clinical Development
• Table 16: New Cancer Vaccine Target Combinations in Phase II Clinical Development
• Table 17 New Cancer Vaccine Target Combinations Phase I Clinical Development
• Table 18: New Cancer Vaccine Target Combinations in Preclinical Development
• Table 19: Top 5 Pursued Cancer Vaccine Targets
• Table 20: The Progression, Maturity and Comptitive Comparison of Cancer Vaccine Target Mixes in Development
• Table 21: Number of Cancer Vaccine Drug Target Mixes Reported by Cancer Indication
• Table 22: Locating Your Competitors/Peers - Step 1
• Table 23: Locating Your Competitors/Peers - Step 2
• Table 24: Drug Targets of Cancer Vaccines for the Treatment of Anal Dysplasia According to the Compound Type and Developmental Stage of Vaccine
• Table 25: Drug Targets of Cancer Vaccines for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 26: Drug Targets of Cancer Vaccines for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 27: Drug Targets of Cancer Vaccines for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 28: Drug Targets of Cancer Vaccines for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 29: Drug Targets of Cancer Vaccines for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 30: Drug Targets of Cancer Vaccines for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 31: Drug Targets of Cancer Vaccines for the Treatment of Cervical Dysplasia According to the Compound Type and Developmental Stage of Vaccine
• Table 32: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Bone Marrow Injury (General) According to the Compound Type and Developmental Stage of Vaccine
• Table 33: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Neutropenia According to the Compound Type and Developmental Stage of Vaccine
• Table 34: Drug Targets of Cancer Vaccines for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 35: Drug Targets of Cancer Vaccines for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 36: Drug Targets of Cancer Vaccines for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 37: Drug Targets of Cancer Vaccines for the Treatment of Leukemia (General) According to the Compound Type and Developmental Stage of Vaccine
• Table 38: Drug Targets of Cancer Vaccines for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Vaccine
• Table 39: Drug Targets of Cancer Vaccines for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Vaccine
• Table 40: Drug Targets of Cancer Vaccines for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Vaccine
• Table 41: Drug Targets of Cancer Vaccines for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 42: Drug Targets of Cancer Vaccines for the Treatment of Lung Cancer (General) According to the Compound Type and Developmental Stage of Vaccine
• Table 43: Drug Targets of Cancer Vaccines for the Treatment of Non Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 44 Drug Targets of Cancer Vaccines for the Treatment of Small Cell Lung According to the Compound Type and Developmental Stage of Vaccine
• Table 45: Drug Targets of Cancer Vaccines for the Treatment of Lymphoma (General) According to the Compound Type and Developmental Stage of Vaccine
• Table 46: Drug Targets of Cancer Vaccines for the Treatment of B-Cell Lymphoma According to the Compound Type and Developmental Stage of Vaccine
• Table 47: Drug Targets of Cancer Vaccines for the Treatment of non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Vaccine
• Table 48: Drug Targets of Cancer Vaccines for the Treatment of T-Cell Lymphoma According to the Compound Type and Developmental Stage of Vaccine
• Table 49: Drug Targets of Cancer Vaccines for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Vaccine
• Table 50: Drug Targets of Cancer Vaccines for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Vaccine
• Table 51: Drug Targets of Cancer Vaccines for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 52: Drug Targets of Cancer Vaccines for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 53: Drug Targets of Cancer Vaccines for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 54: Drug Targets of Cancer Vaccines for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 55: Drug Targets of Cancer Vaccines for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 56: Drug Targets of Cancer Vaccines for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 57: Drug Targets of Cancer Vaccines for the Treatment of Sarcoma According to the Compound Type and Developmental Stage of Vaccine
• Table 58: Drug Targets of Cancer Vaccines for the Treatment of Skin Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 59: Drug Targets of Cancer Vaccines for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Vaccine
• Table 60: Drug Targets of Cancer Vaccines for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Vaccine
• Table 61: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Australia
• Table 62: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Canada
• Table 63: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in China
• Table 64: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Denmark
• Table 65: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in France
• Table 66: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Germany
• Table 67: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in India
• Table 68: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Israel
• Table 69: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Italy
• Table 70: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Japan
• Table 71: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in the Netherlands
• Table 72: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Norway
• Table 73: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in South Korea
• Table 74: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Switzerland
• Table 75: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in United Kingdom
• Table 76: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in USA
• Table 77: Cancer Vaccines with Drug Target Mix and Developmental Projects by Non-Industrial Bodies

Protein Kinase Inhibitors

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Figures
• 4.2 List of Tables

5 Introduction

6 PKI Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Protein Kinase Inhibitors

• 7.1 PKI Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Protein Expression Profiles of PKI Drug Targets in Human

• 8.1 Expression in Normal Tissues and Cancer Tissues
• 8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Protein Kinase Inhibitors in Major Cell Signaling Pathways

• 9.1 Alpha6 Beta4 Integrin Signaling Pathway
• 9.2 Androgen Receptor Signaling Pathway
• 9.3 B Cell Receptor Signaling Pathway
• 9.4 EGFR1 Signaling Pathway
• 9.5 Hedgehog Signaling Pathway
• 9.6 ID Signaling Pathway
• 9.7 IL-1 Signaling Pathway
• 9.8 IL-2 Signaling Pathway
• 9.9 IL-3 Signaling Pathway
• 9.10 IL-4 Signaling Pathway
• 9.11 IL-5 Signaling Pathway
• 9.12 IL-6 Signaling Pathway
• 9.13 IL-7 Signaling Pathway
• 9.14 IL-9 Signaling Pathway
• 9.15 Kit Receptor Signaling Pathway
• 9.16 Notch Signaling Pathway
• 9.17 T Cell Receptor Signaling Pathway
• 9.18 TGF-beta Receptor Signaling Pathway
• 9.19 TNF-alpha Signaling Pathway
• 9.20 Wnt Signaling Pathway

10 Protein-Protein Interactions Between Identified PKI Drug Targets

11 Available Biological Structure Data on PKI Drug Targets

12 Drug Target Profiles of Protein Kinase Inhibitory Drug Targets in Oncology

• 12.1 Kinase Activity Target
  • 12.1.1 Kinase Activity
  • 12.1.2 Protein Serine/Threonine Kinase Activity
  • 12.1.3 Lipid Kinase Activity
  • 12.1.4 Protein Threonine/Tyrosine Kinase Activity
  • 12.1.5 Protein-Tyrosine Kinase Activity
  • 12.1.6 Receptor Activity
  • 12.1.7 Receptor Signaling Protein Serine/Threonine Kinase Activity
  • 12.1.8 Transmembrane Receptor Protein Tyrosine Kinase Activity
• 12.2 Non Kinase Activity Targets
  • 12.2.1 Carboxy-lyase Activity
  • 12.2.2 Cell Adhesion Molecule Activity
  • 12.2.3 Chaperone activity
  • 12.2.4 Cysteine-type Peptidase Activity
  • 12.2.5 DNA Topoisomerase Activity
  • 12.2.6 DNA-Directed DNA Polymerase Activity
  • 12.2.7 Growth Factor Activity
  • 12.2.8 Hormone Activity
  • 12.2.9 Hydrolase Activity
  • 12.2.10 Kinase Regulator Activity
  • 12.2.11 Ligase Activity
  • 12.2.12 Lipid Phosphatase Activity
  • 12.2.13 Oxidoreductase Activity
  • 12.2.14 Protein Binding
  • 12.2.15 Receptor Binding
  • 12.2.16 Receptor Signaling Complex Scaffold Activity
  • 12.2.17 RNA Binding
  • 12.2.18 Structural Constituent of Cytoskeleton
  • 12.2.19 Transcription Factor Activity
  • 12.2.20 Transcription Regulator Activity
  • 12.2.21 Translation Regulator Activity
  • 12.2.22 Transporter Activity

13 Protein Kinase Inhibitor Drug Target Mix by Cancer Indications

• 13.1 Basal Cell Cancer
• 13.2 Biliary Cancer
• 13.3 Bladder Cancer
• 13.4 Bone Cancer
• 13.5 Brain Cancer
• 13.6 Breast Cancer
• 13.7 Carcinoid
• 13.8 Cervical Cancer
• 13.9 Cervical Dysplasia
• 13.10 Chemotherapy-induced Bone Marrow Anemia
• 13.11 CNS Cancer
• 13.12 Colorectal Cancer
• 13.13 Endometrial Cancer
• 13.14 Fallopian Tube Cancer
• 13.15 Gastrointestinal Cancer
• 13.15.1 Gastrointestinal Stomach Cancer
• 13.15.2 Gastrointestinal Stromal Cancer
• 13.16 Head and Neck Cancer
• 13.17 Leukemia
• 13.17.1 Acute Lymphocytic Leukemia
• 13.17.2 Acute Myelogenous Leukemia
• 13.17.3 Chronic Lymphocytic Leukemia
• 13.17.4 Chronic Myelogenous Leukemia
• 13.18 Liver Cancer
• 13.19 Lung Cancer
• 13.19.1 Non-Small Cell Lung Cancer
• 13.19.2 Small Cell Lung Cancer
• 13.20 Lymphoma
• 13.20.1 B-cell Lymphoma
• 13.20.2 Hodgkin' s Lymphoma
• 13.20.3 Non-Hodgkin`s Lymphoma
• 13.20.4 T-